Events - ISN Middle East Regional Board webinar: Non-Immunosuppressive treatment for IgA Nephropathy – bridging the gap between knowledge and practice

Non-immunosuppressive management of IgA nephropathy has evolved significantly over the past decades. Early strategies—including omega-3 fatty acids, antiplatelet agents, statins, Chinese herbal medicines, and tonsillectomy—produced inconsistent results. The introduction of renin-angiotensin system blockers (ACE inhibitors and ARBs) became a cornerstone in reducing proteinuria, yet their long-term impact on kidney function preservation remains limited. 

Supportive measures such as blood pressure control, weight management, and lipid lowering have been widely recommended, but their efficacy in halting disease progression has been modest. 

In recent years, the treatment landscape has shifted with the advent of novel agents such as SGLT2 inhibitors and endothelin receptor antagonists, offering new avenues for effective, non-immunosuppressive intervention. 

This webinar will feature expert talks on “Expanding the Horizons of Non-Immunosuppressive Management in IgA Nephropathy” and “Endothelin Receptor Blockers in IgA Nephropathy”, highlighting emerging data, clinical applications, and practical considerations for integrating these therapies into patient care. Join us as we explore the latest advances and discuss how to bridge the gap between evolving evidence and clinical practice in the Middle East and beyond.